GSK plc
GSK
$46.63
-$0.47-1.00%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 3,696.29% | 30.27% | 54.21% | 21.95% | -104.07% |
| Total Depreciation and Amortization | -19.59% | 92.06% | 48.89% | -50.66% | 68.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | 7.16% | -- |
| Total Other Non-Cash Items | 89.97% | 75.56% | 424.46% | 305.44% | -365.39% |
| Change in Net Operating Assets | -130.51% | -37.79% | -129.08% | -128.73% | 562.89% |
| Cash from Operations | 6.89% | 99.42% | 18.71% | -24.87% | 0.08% |
| Capital Expenditure | -5.66% | 10.24% | 16.70% | -15.40% | -4.84% |
| Sale of Property, Plant, and Equipment | 418.10% | 164.73% | -0.67% | 798.43% | -90.66% |
| Cash Acquisitions | -22,178.29% | 90.37% | -10.47% | -3,250.75% | 93.47% |
| Divestitures | 134.54% | -323.57% | 66.89% | 26.36% | -54.16% |
| Other Investing Activities | 9.70% | -132.72% | -116.05% | -177.19% | -212.81% |
| Cash from Investing | -117.02% | -185.95% | -662.59% | -530.47% | -53.02% |
| Total Debt Issued | -- | -- | -- | 195.17% | -- |
| Total Debt Repaid | 89.74% | -163.76% | 43.16% | 18.23% | -25.05% |
| Issuance of Common Stock | -100.00% | 100.00% | -33.33% | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -10.05% | -6.54% | -7.02% | -11.08% | -10.94% |
| Other Financing Activities | -724.00% | 31.75% | -20.00% | -102.91% | 74.23% |
| Cash from Financing | -9.89% | -58.57% | 180.40% | 75.83% | 27.67% |
| Foreign Exchange rate Adjustments | 279.81% | -244.15% | 42.50% | 121.23% | -251.93% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -492.92% | -437.33% | 411.95% | 338.65% | 950.78% |